Opportunities this week:

Following on from Roche’s mixed set of full year results at the end of January, but also with a solid guide for 2025 we reiterate our BUY rating on the name with an updated price target of CHF 330.
We continue to believe there is potential for IRES REIT to reduce the wide discount (26%) it trades at relative to its Net Aset Value (NAV). We have now added IRES to the ACL. BUY PT: €1.19.
Shares in LVMH are down 9% since its FY24 earnings release a couple of weeks ago, which now means there is 16% upside to our €790 price target. As such, on weakness, we are upgrading the stock to BUY.